Penumbra Q3 2020 Earnings Report
Key Takeaways
Penumbra, Inc. reported a revenue of $151.1 million for the third quarter of 2020, representing an 8.3% increase compared to the third quarter of 2019. The company experienced growth in US revenue, particularly in vascular products, while facing declines in international and neuro product revenues. Operating loss for the quarter was $20.2 million.
Total revenue increased to $151.1 million, up 8.3% from Q3 2019.
US revenue reached $109.7 million, a 22% increase year-over-year.
Vascular product sales grew to $75.2 million, a 33.6% increase.
Neuro product sales declined to $75.9 million, an 8.8% decrease.
Penumbra
Penumbra
Penumbra Revenue by Segment
Penumbra Revenue by Geographic Location
Forward Guidance
Due to the uncertain scope and duration of the pandemic, the global resurgence of cases, and uncertain timing of global recovery and economic normalization, we still cannot reliably estimate the future impact of the pandemic. Further, we think the on-going impact of the pandemic in the United States and other parts of the world could cause periodic disruption in our revenue until the pandemic is contained.
Revenue & Expenses
Visualization of income flow from segment revenue to net income